Physician profile
Harold M Hoffman
NPI 1326074261
$75,727.15
in general payments reported to CMS, 2019-2025
35 companies · $17K in 2025
The $17K reported for 2025 was more than what 91% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $11K · 2021: $1,598 · 2022: $7,239 · 2023: $4,791 · 2024: $21K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Travel and Lodging: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,500 · Food and Beverage: $3,888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,238.11 |
| Travel and Lodging | $12,990.58 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,500.00 |
| Food and Beverage | $3,888.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $23,240.25 | 2019-2025 | |
| Swedish Orphan Biovitrum Ab | $20,124.96 | 2024 | |
| Pharming Healthcare, INC. | $9,023.76 | 2021-2025 | Joenja, Ruconest |
| Amgen INC. | $6,931.91 | 2024-2025 | Actimmune |
| Sobi, INC | $3,613.54 | 2019-2025 | |
| Astellas Pharma INC | $3,600.00 | 2022 | |
| Abbvie INC. | $2,285.95 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $699.18 | 2019-2025 | |
| Grifols USA, LLC | $688.78 | 2021-2025 | Xembify, Gamunex-C |
| Glaxosmithkline, LLC. | $530.81 | 2019-2025 | Nucala |
| Genzyme Corporation | $502.49 | 2022-2025 | |
| Csl Behring | $482.09 | 2019-2025 | Hizentra, Andembry |
| Pfizer INC. | $463.44 | 2020-2025 | |
| Alk-Abello, INC | $449.30 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $362.96 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $341.00 | 2025 | |
| Kaleo, INC. | $314.85 | 2019-2024 | Auvi-Q |
| Shire North American Group INC | $302.92 | 2019 | |
| Biocryst US Sales Co., LLC | $231.85 | 2021-2023 | Orladeyo |
| Genentech USA, INC. | $228.63 | 2019-2024 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $181.05 | 2020-2025 | Cuvitru, Takhzyro |
| Bio Products Laboratory USA, INC. | $153.41 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $151.25 | 2019-2020 | |
| Galderma Laboratories, L.P. | $142.52 | 2025 | Nemluvio |
| Horizon Therapeutics Plc | $135.19 | 2020-2021 | |
| Kedrion Biopharma, INC. | $110.00 | 2022 | |
| Kiniksa Pharmaceuticals, Ltd. | $107.66 | 2021 | |
| Leo Pharma INC. | $101.56 | 2023 | Adbry |
| Genentech, INC. | $83.41 | 2022 | |
| Adma Biomanufacturing LLC | $31.96 | 2025 | |
| Greer Laboratories, INC. | $25.98 | 2023 | Palforzia |
| Octapharma USA, INC. | $25.51 | 2024 | Cutaquig |
| Hospira, INC. | $24.78 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $20.74 | 2025 | Neffy |
| Grifols Shared Services North America, INC. | $13.46 | 2025 | Xembify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.